Koichi Azuma

Kurume University School of Medicine
Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (15)

Purpose: This study was performed to confirm the superiority in overall survival (OS) of EGFR tyrosine kinase inhibitor (TKI gefitinib or osimertinib) monotherapy versus EGFR TKI with intercalation of cisplatin plus pemetrexed as the first-line treatment for patients with advanced non-squamous non–small cell lung cancer (NSqNSCLC) harboring EGFR mutation. Patients and Methods: This was an open-label, multicenter, randomized phase III study. Patients with chemotherapy-naïve advanced or recurrent NSqNSCLC harboring EGFR mutation (exon 19 deletion or exon 21 L858R point mutation) were randomly assigned (1:1) to EGFR-TKI monotherapy or the EGFR TKI plus intercalated chemotherapy group. The primary endpoint was OS, and the secondary endpoints included progression-free survival (PFS). Results: From December 2015 to October 2020, 501 patients were randomized. The EGFR TKI was changed from gefitinib to osimertinib in October 2018 (gefitinib cohort: n = 308 and osimertinib cohort: n = 193). There was no survival advantage in the EGFR TKI plus intercalated chemotherapy group; the median survival time of both groups was 48.0 months (HR, 0.985; 91.4% confidence interval, 0.796–1.219; one-sided P = 0.4496). The median PFS time was 12.0 months in the EGFR-TKI monotherapy group and 18.0 months in the EGFR TKI plus intercalated chemotherapy group (HR, 0.762; 95% confidence interval, 0.628–0.925; one-sided P = 0.003). The OS and PFS trends in both gefitinib and osimertinib cohorts were identical to those in the entire population. Conclusions: The intercalation of cisplatin plus pemetrexed after the response to EGFR TKI improved PFS but not OS compared with EGFR TKI monotherapy as the first-line treatment for patients with advanced NSqNSCLC harboring EGFR mutation.

Year:

2025

Supplementary Figure S3. Subgroup analyses of overall survival. (A) Gefitinib cohort. (B) Osimertinib cohort. Abbreviations: CI, confidence interval; EGFR, epidermal growth factor receptor; Ex19del, EGFR exon 19 deletion; L858R, EGFR exon 21 L858 point mutation; ECOG, Eastern Clinical Oncology group; PS, performance status; EGFR-TKI, epidermal growth factor receptor tyrosine kinase inhibitor; CNS, central nervous system.

Year:

2025

Kaplan–Meier analysis of OS. A, ITT population. The 1-, 2-, 3-, 4-, and 5-year survival rates were 92.8%, 80.4%, 63.5%, 49.6%, and 36.9% in the control group and 94.4%, 81.7%, 69.9%, 49.9%, and 35.3% in the experimental group, respectively. B, Gefitinib cohort. The 1-, 2-, 3-, 4-, and 5-year survival rates were 91.5%, 78.4%, 59.5%, 46.3%, and 34.4% in the control group and 92.2%, 77.7%, 66.4%, 46.5%, and 32.9% in the experimental group, respectively. C, Osimertinib cohort. The 1-, 2-, and 3-year survival rates were 94.8%, 83.4%, and 69.8% in the control group and 97.9%, 88.3%, and 76.0% in the experimental group, respectively. D, Subgroup analysis of OS. ECOG, Eastern Clinical Oncology Group; Ex19del, EGFR exon 19 deletion; L858R, EGFR exon 21 L858 point mutation; NE; not estimable; PS, performance status.

Year:

2025

Kaplan–Meier analysis of PFS. A, ITT population. The 1-, 2-, 3-, 4-, and 5-year PFS rates were 49.2%, 26.0%, 18.0%, 12.9%, and 7.8% in the control group and 67.0%, 39.8%, 24.1%, 11.9%, and 9.5% in the experimental group, respectively. B, Gefitinib cohort. The 1-, 2-, 3-, 4-, and 5-year PFS rates were 37.3%, 13.7%, 8.5%, 6.5%, and 4.0% in the control group and 59.5%, 32.7%, 15.7%, 7.2%, and 5.7% in the experimental group, respectively. C, Osimertinib cohort. The 1-, 2-, and 3-year PFS rates were 68.0%, 45.3%, and 32.2% in the control group and 79.0%, 51.4%, and 39.6% in the experimental group, respectively. D, Subgroup analysis of PFS. ECOG, Eastern Clinical Oncology Group; Ex19del, EGFR exon 19 deletion; L858R, EGFR exon 21 L858 point mutation; PS, performance status.

Year:

2025

Supplementary Figure S4. Subgroup analyses of progression-free survival. (A) Gefitinib cohort. (B) Osimertinib cohort. Abbreviations: CI, confidence interval; EGFR, epidermal growth factor receptor; Ex19del, EGFR exon 19 deletion; L858R, EGFR exon 21 L858 point mutation; ECOG, Eastern Clinical Oncology group; PS, performance status; EGFR-TKI, epidermal growth factor receptor tyrosine kinase inhibitor; CNS, central nervous system.

Year:

2025

Supplementary Figure S2. Study design of JCOG1404/WJOG8214L. Abbreviations: NSCLC, non-small cell lung cancer; EGFR; epidermal growth factor receptor; Exon 19 DEL, EGFR exon 19 deletion; Exon 21 L858R, EGFR exon 21 L858 point mutation; ECOG, Eastern Clinical Oncology Group; PS, performance status; CNS, central nervous system; EGFR-TKI, epidermal growth factor receptor tyrosine kinase inhibitor; PD, progressive disease.

Year:

2025

Purpose: E7389-LF is a liposomal formulation of eribulin that contributes to tumor vascular remodeling. The phase II part of this phase Ib/II study assessed the efficacy/safety of E7389-LF in combination with nivolumab in several disease cohorts; herein, we report results from the small cell lung cancer (SCLC) cohort. Experimental Design: Patients with unresectable/measurable SCLC and disease progression with first-line platinum-based chemotherapy with/without an immune checkpoint inhibitor (ICI) were enrolled to receive E7389-LF 2.1 mg/m2 plus nivolumab 360 mg intravenously every 3 weeks. The primary objective of this part was to assess the objective response rate (ORR). Secondary objectives included assessments of safety and progression-free survival (PFS); exploratory assessments included overall survival (OS) and biomarkers. Results: Thirty-four patients were enrolled. By the data cut-off date (May 31, 2022), 29 (85.3%) had discontinued. Efficacy/biomarker analyses included 33 patients (1 had their diagnosis changed postenrollment); the ORR of E7389-LF plus nivolumab was 24.2% [95% confidence interval (CI): 11.1–42.3], the median PFS was 3.98 months (95% CI: 2.63–4.40), and, at a median follow-up of 10.6 months, the median OS was not reached (95% CI: not estimable). Notably, 27 of 33 patients (81.8%) had received an ICI as their prior first-line therapy. Treatment-related, treatment-emergent adverse events occurred in 97.1% (any grade) and 82.4% (grade ≥3) of enrolled patients; the most common event was neutropenia. Changes in vascular and immune-related plasma markers were observed. Conclusions: E7389-LF 2.1 mg/m2 in combination with nivolumab 360 mg every 3 weeks showed notable antitumor activity as second-line therapy for SCLC; no new safety signals were observed compared with either agent as monotherapy. Significance: This phase II part of a phase Ib/II study assessed liposomal eribulin (E7389-LF) plus nivolumab in 34 patients with pretreated SCLC; 8 of 33 evaluable patients (including 6/27 pretreated with ICIs) had objective responses. The combination was tolerable; increases in vasculature-related biomarkers tended to correlate with responses.

Year:

2024

Purpose: E7389-LF is a liposomal formulation of eribulin that contributes to tumor vascular remodeling. The phase II part of this phase Ib/II study assessed the efficacy/safety of E7389-LF in combination with nivolumab in several disease cohorts; herein, we report results from the small cell lung cancer (SCLC) cohort. Experimental Design: Patients with unresectable/measurable SCLC and disease progression with first-line platinum-based chemotherapy with/without an immune checkpoint inhibitor (ICI) were enrolled to receive E7389-LF 2.1 mg/m 2 plus nivolumab 360 mg intravenously every 3 weeks. The primary objective of this part was to assess the objective response rate (ORR). Secondary objectives included assessments of safety and progression-free survival (PFS); exploratory assessments included overall survival (OS) and biomarkers. Results: Thirty-four patients were enrolled. By the data cut-off date (May 31, 2022), 29 (85.3%) had discontinued. Efficacy/biomarker analyses included 33 patients (1 had their diagnosis changed postenrollment); the ORR of E7389-LF plus nivolumab was 24.2% [95% confidence interval (CI): 11.1–42.3], the median PFS was 3.98 months (95% CI: 2.63–4.40), and, at a median follow-up of 10.6 months, the median OS was not reached (95% CI: not estimable). Notably, 27 of 33 patients (81.8%) had received an ICI as their prior first-line therapy. Treatment-related, treatment-emergent adverse events occurred in 97.1% (any grade) and 82.4% (grade ≥3) of enrolled patients; the most common event was neutropenia. Changes in vascular and immune-related plasma markers were observed. Conclusions: E7389-LF 2.1 mg/m 2 in combination with nivolumab 360 mg every 3 weeks showed notable antitumor activity as second-line therapy for SCLC; no new safety signals were observed compared with either agent as monotherapy. Significance: This phase II part of a phase Ib/II study assessed liposomal eribulin (E7389-LF) plus nivolumab in 34 patients with pretreated SCLC; 8 of 33 evaluable patients (including 6/27 pretreated with ICIs) had objective responses. The combination was tolerable; increases in vasculature-related biomarkers tended to correlate with responses.

Year:

2024

Changes from baseline in select vasculature and IFN-related biomarkers weekly to C3D1 ( A ), per cycle to C8D1 ( B ), by tumor response (for vasculature-related biomarkers; C ), and by presence of prior ICI treatment (for IFN-related biomarkers; D ). Lines represent medians; error bars represent 95% CI. For box-and-whisker plots in C, the horizontal line represents the median, the box represents the interquartile range, the whiskers represent the largest or smallest values within 1.5 times the interquartile range (either above the 75th percentile or below the 25th percentile), and diamonds represent outliers. P values are: *, P P P A : n = 33 (C1D1, C1D8), n = 32 (C1D15), n = 30 (C2D1), n = 29 (C2D8), n = 28 (C2D15), n = 25 (C3D1). B : n = 33 (C1D1). n = 30 (C2D1), n = 25 (C3D1), n = 24 (C4D1), n = 19 (C5D1), n = 12 (C6D1), n = 8 (C7D1), n = 7 (C8D1). C : for CR/PR, n = 8 (C2D1, C3D1, C4D1); for non-CR/PR, n = 22 (C2D1), n = 17 (C3D1), n = 16 (C4D1). D : for prior ICI, n = 27 (C1D1, C1D8), n = 26 (C1D15), n = 25 (C2D1, C2D8, C2D15), n = 20 (C3D1); for no prior ICI, n = 6 (C1D1, C1D8, C1D15), n = 5 (C2D1), n = 4 (C2D8), n = 3 (C2D15), n = 5 (C3D1). C#D#, cycle #, day; CR, complete response; ICI, immune checkpoint inhibitor; IFNγ, interferon gamma; IP-10, IFN gamma-induced protein 10; MIG, monokine induced by gamma IFN; PECAM1, platelet endothelial cell adhesion molecule 1; PR, partial response; TEK, TEK receptor tyrosine kinase; TIE2, tyrosine kinase immunoglobulin and EGF homology domains 2.

Year:

2024

Swimmer plots of patients by course of treatment and dose reduction of E7389-LF ( A ) and lines of subsequent therapies received during survival follow-up ( B ). Patients could continue to receive study drugs beyond disease progression if they had investigator-assessed clinical benefit and were tolerating study drugs. This figure includes data from beyond disease progression. #L, line of treatment number; AE, adverse event; BSC, best supportive care; PD, progressive disease; PR, partial response.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (10)

Shintaro Kanda

Professor

Shinshu University

JAPAN
View details

Yuko Oya

senoor Assistant Professor

Fujita Health University

JAPAN
View details

Hirokazu Taniguchi

Senior Assistant Professor

Nagasaki University Hospital

JAPAN
View details

Takayasu Kurata

-

JAPAN
View details

Yutaka Fujiwara

Head

Aichi Cancer Center

JAPAN
View details

Shogo Nomura

Associate Professor

University of Tokyo

JAPAN
View details

Eiji Iwama

Kyushu University

JAPAN
View details

Toshiyuki Kozuki

Kochi Medical School, Kochi University

JAPAN
View details

Seiji Niho

-

JAPAN
View details

Daichi Fujimoto

Hyogo medical university

JAPAN
View details